A randomised, double blind, placebo controlled, 48-week clinical trial with a core population
(group A) of 79 ambulant 6.5 to 12 years old Duchenne's muscular dystrophy (DMD) patients
that are under stable standard treatment of care with glucocorticoids. Furthermore, the
investigators plan to include 6-20 non-ambulant patients who do not receive glucocorticoids
(as parallel group B), 10 to 16 years old, to obtain efficacy and safety data in a broader
DMD population. All patients will receive 20 mg of tamoxifen (TAM) or placebo once daily
during 48 weeks.
An open label extension (OLE) trial for participants of the TAMDMD main study will be
performed. All TAMDMD patients on TAM or placebo are offered to enter this OLE.